CABA Quote, Financials, Valuation and Earnings

CorMedix, Inc. has a net margin of -- compared to Cabaletta Bio, Inc.'s net margin of 49.9%. Cabaletta Bio, Inc.'s return on equity of -103.46% beat CorMedix, Inc.'s return on equity of 95.25%.

Cabaletta Bio, Inc. has a consensus price target of $14.13, signalling upside risk potential of 451.76%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 78.57%. Given that Cabaletta Bio, Inc. has higher upside potential than CorMedix, Inc., analysts believe Cabaletta Bio, Inc. is more attractive than CorMedix, Inc..

Cabaletta Bio, Inc. has a beta of 3.171, which suggesting that the stock is 217.108% more volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.

Cabaletta Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio, Inc. pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.

Cabaletta Bio, Inc. quarterly revenues are --, which are smaller than CorMedix, Inc. quarterly revenues of $104.3M. Cabaletta Bio, Inc.'s net income of -$44.9M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Cabaletta Bio, Inc.'s price-to-earnings ratio is -- while CorMedix, Inc.'s PE ratio is 5.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio, Inc. is -- versus 3.58x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ocugen, Inc. has a net margin of -- compared to Cabaletta Bio, Inc.'s net margin of -1144.46%. Cabaletta Bio, Inc.'s return on equity of -103.46% beat Ocugen, Inc.'s return on equity of -345.08%.

Cabaletta Bio, Inc. has a consensus price target of $14.13, signalling upside risk potential of 451.76%. On the other hand Ocugen, Inc. has an analysts' consensus of $9.00 which suggests that it could grow by 625.81%. Given that Ocugen, Inc. has higher upside potential than Cabaletta Bio, Inc., analysts believe Ocugen, Inc. is more attractive than Cabaletta Bio, Inc..

Cabaletta Bio, Inc. has a beta of 3.171, which suggesting that the stock is 217.108% more volatile than S&P 500. In comparison Ocugen, Inc. has a beta of 4.540, suggesting its more volatile than the S&P 500 by 354.007%.

Cabaletta Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio, Inc. pays -- of its earnings as a dividend. Ocugen, Inc. pays out -- of its earnings as a dividend.

Cabaletta Bio, Inc. quarterly revenues are --, which are smaller than Ocugen, Inc. quarterly revenues of $1.8M. Cabaletta Bio, Inc.'s net income of -$44.9M is lower than Ocugen, Inc.'s net income of -$20.1M. Notably, Cabaletta Bio, Inc.'s price-to-earnings ratio is -- while Ocugen, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio, Inc. is -- versus 68.06x for Ocugen, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cartesian Therapeutics, Inc. has a net margin of -- compared to Cabaletta Bio, Inc.'s net margin of -7942.92%. Cabaletta Bio, Inc.'s return on equity of -103.46% beat Cartesian Therapeutics, Inc.'s return on equity of --.

Cabaletta Bio, Inc. has a consensus price target of $14.13, signalling upside risk potential of 451.76%. On the other hand Cartesian Therapeutics, Inc. has an analysts' consensus of $35.29 which suggests that it could grow by 411.39%. Given that Cabaletta Bio, Inc. has higher upside potential than Cartesian Therapeutics, Inc., analysts believe Cabaletta Bio, Inc. is more attractive than Cartesian Therapeutics, Inc..

Cabaletta Bio, Inc. has a beta of 3.171, which suggesting that the stock is 217.108% more volatile than S&P 500. In comparison Cartesian Therapeutics, Inc. has a beta of 0.506, suggesting its less volatile than the S&P 500 by 49.39%.

Cabaletta Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cartesian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio, Inc. pays -- of its earnings as a dividend. Cartesian Therapeutics, Inc. pays out -- of its earnings as a dividend.

Cabaletta Bio, Inc. quarterly revenues are --, which are smaller than Cartesian Therapeutics, Inc. quarterly revenues of $452K. Cabaletta Bio, Inc.'s net income of -$44.9M is lower than Cartesian Therapeutics, Inc.'s net income of -$35.9M. Notably, Cabaletta Bio, Inc.'s price-to-earnings ratio is -- while Cartesian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio, Inc. is -- versus 76.98x for Cartesian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Verastem, Inc. has a net margin of -- compared to Cabaletta Bio, Inc.'s net margin of -876.34%. Cabaletta Bio, Inc.'s return on equity of -103.46% beat Verastem, Inc.'s return on equity of -1773.4%.

Cabaletta Bio, Inc. has a consensus price target of $14.13, signalling upside risk potential of 451.76%. On the other hand Verastem, Inc. has an analysts' consensus of $16.00 which suggests that it could grow by 59.05%. Given that Cabaletta Bio, Inc. has higher upside potential than Verastem, Inc., analysts believe Cabaletta Bio, Inc. is more attractive than Verastem, Inc..

Cabaletta Bio, Inc. has a beta of 3.171, which suggesting that the stock is 217.108% more volatile than S&P 500. In comparison Verastem, Inc. has a beta of 0.412, suggesting its less volatile than the S&P 500 by 58.798%.

Cabaletta Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Verastem, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cabaletta Bio, Inc. pays -- of its earnings as a dividend. Verastem, Inc. pays out -- of its earnings as a dividend.

Cabaletta Bio, Inc. quarterly revenues are --, which are smaller than Verastem, Inc. quarterly revenues of $11.2M. Cabaletta Bio, Inc.'s net income of -$44.9M is higher than Verastem, Inc.'s net income of -$98.5M. Notably, Cabaletta Bio, Inc.'s price-to-earnings ratio is -- while Verastem, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cabaletta Bio, Inc. is -- versus 47.01x for Verastem, Inc.. Usually stocks with elevated PS ratios are considered overvalued.